Switching from one infliximab biosimilar (CT‐P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis. (13th April 2020) - Gisondi, P.; Virga, C.; Piaserico, S.; Meneguzzo, A.; Odorici, G.; Conti, A.; Girolomoni, G.